Theratechnologies inc.
TSX : TH

Theratechnologies inc.

June 17, 2008 16:33 ET

Notice of Conference Call & Media Advisory: Theratechnologies Reports 26-week Confirmatory Phase 3 Results

Attention Business/Financial Editors and Analysts

MONTREAL, QUEBEC--(Marketwire - June 17, 2008) - Theratechnologies (TSX:TH) advises of an upcoming conference call and webcast to discuss the 26-week results of its confirmatory Phase 3 clinical trial, testing tesamorelin, in patients with HIV-associated lipodystrophy. The call will be moderated by Dr. Andrea Gilpin, Vice President, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Mr. Luc Tanguay, Senior Executive Vice President and Chief Financial Officer, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating.

The conference call will take place tomorrow, June 18, at 7:30 a.m. Eastern Time. Prior to the call, a press release will be issued at approximately 6:45 a.m.

June 18, 2008 conference call and webcast

For the conference call, interested participants are asked to dial the following numbers: 416-644-3415 or 1-800-733-7571 (toll free). Please call five minutes prior to the conference in order to ensure your participation. You can access the webcast at the following links: www.investorcalendar.com and www.theratech.com.

A replay of the conference call will be available from June 18, 2008 at 9:30 a.m. to June 25, 2008 at 11:59 p.m. at the following number: 416-640-1917, pass code 21275389# or 1-877-289-8525, code 21275389#. The webcast will be posted for 10 days at the following links: www.investorcalendar.com and www.theratech.com.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Contact Information